Previously, a proposed approach to the management of EGFR-mutant NSCLC progression on osimertinib was recommended: tumor biopsy of the progressive site should be accessed for evaluation of resistant mechanisms to indicate subsequent treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.